CANCER CAPITAL CORP financial data

Location
Salt Lake City, UT
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 21 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2% % -50%
Debt-to-equity -100% % 3.6%
Return On Equity 9.3% % -2.3%
Return On Assets -456% % -101%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,150,000 shares
Common Stock, Shares, Outstanding 6,150,000 shares
Common Stock, Value, Issued $6,150 USD 0%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $19,945 USD 12%
Operating Income (Loss) $19,945 USD -12%
Net Income (Loss) Attributable to Parent $43,380 USD -7.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,109 USD -73%
Assets, Current $4,109 USD -73%
Assets $4,109 USD -73%
Liabilities, Current $487,713 USD 7.1%
Liabilities $487,713 USD 7.1%
Retained Earnings (Accumulated Deficit) $536,804 USD -8.8%
Stockholders' Equity Attributable to Parent $483,604 USD -9.9%
Liabilities and Equity $4,109 USD -73%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,500 USD 17%
Common Stock, Shares Authorized 20,000,000 shares
Common Stock, Shares, Issued 6,150,000 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,500 USD 17%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,109 USD -73%
Additional Paid in Capital $47,050 USD 0%
Interest Expense $10,423 USD 0.7%